Press Releases

InVivo Therapeutics to Present at Cell & Gene Meeting on the Mesa

Published: September 26, 2016

CAMBRIDGE, Mass. (Sept 26, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Thomas Ulich, M.D., Chief Scientific Officer, will present at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa, to be held October 5-7 in La Jolla, California. The company’s presentation will be on October 6 at 4:00 PM (PDT). A live webcast will be available at http://www.meetingonthemesa.com/webcast/ and will also be published on the Alliance for Regenerative Medicine (ARM)’s website shortly after the event. Organized by ARM and the Sanford Consortium for Regenerative Medicine, the Cell & Gene Meeting on the […]

View Article
InVivo Therapeutics Announces Late-Breaking Oral Presentation at the 2016 Congress of Neurological Surgeons Annual Meeting

Published: September 20, 2016

CAMBRIDGE, Mass. (Sept 20, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Michael Fehlings, M.D., Ph.D., Director of the Spinal Program at the Krembil Neuroscience Centre of Toronto Western Hospital and a Professor of Neurosurgery at the University of Toronto, will give a late- breaking oral presentation titled “Clinical-Pathological Assessment of Severe (AIS A) Traumatic Acute Thoracic Spinal Cord Injury: Post-Durotomy/Myelotomy Observations from the INSPIRE Trial” at the 2016 Congress of Neurological Surgeons (CNS) Annual Meeting on September 28, 2016. The abstract was one of the top three late-breaking abstracts chosen for an oral presentation. “INSPIRE has provided […]

View Article
InVivo Therapeutics Announces Oral Platform Presentation at 2016 Congress of Neurological Surgeons Annual Meeting

Published: September 14, 2016

CAMBRIDGE, Mass. (Sept 14, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Nicholas Theodore, M.D., Director of the John Hopkins Neurosurgical Spine Center, will be giving an oral platform presentation titled “High AIS Grade Conversion Rate Following Neuro-Spinal Scaffold™ Implantation in Acute Thoracic Complete AIS A Spinal Cord Injury (SCI): Potential Mechanisms” at the 2016 Congress of Neurological Surgeons (CNS) Annual Meeting to be held September 24-28, 2016 in San Diego, CA. The presentation will be made on Tuesday, September 27, during the section on Neurotrauma and Critical Care. Dr. Theodore said, “It has been encouraging to watch […]

View Article
InVivo Therapeutics to Present at 55th International Spinal Cord Society Annual Scientific Meeting

Published: September 7, 2016

InVivo Therapeutics Holdings Corp. (NVIV) today announced that Kristin Neff, Vice President of Clinical Operations & Project Management, is scheduled to present at the 55th International Spinal Cord Society (ISCoS) Annual Scientific Meeting to be held September 14-16, 2016 in Vienna, Austria.

View Article
InVivo Therapeutics to Participate in Upcoming Investor Conferences

Published: September 6, 2016

- CEO and Chairman Mark Perrin to Present at Rodman & Renshaw and Ladenburg Thalmann Annual Conferences – CAMBRIDGE, Mass. (Sept 6, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company will participate in two upcoming investor conferences. Mark Perrin, Chief Executive Office and Chairman, is scheduled to present at the Rodman & Renshaw 18th Annual Global Investment Conference in New York, NY on Tuesday, September 13 at 5:05 PM EDT. Additional information about the conference can be found at www.rodm.com  Mr. Perrin is also scheduled to present at Ladenburg Thalmann’s 2nd Annual Healthcare Conference in New […]

View Article
InVivo Therapeutics Announces Northwestern Medicine as New Site for INSPIRE Study

Published: August 18, 2016

CAMBRIDGE, Mass. (Aug 18, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Northwestern Medicine in Chicago, IL has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. Surgeries will be performed at the Northwestern Memorial Hospital, an 894-bed Level I trauma center. “Chicago, as with other major metropolitan areas, sees a disproportionally high number of acute, traumatic spinal cord injuries and unfortunately, with complete spinal cord injuries, trauma teams have limited tools at […]

View Article
InVivo Therapeutics Announces Fifth Patient Conversion in INSPIRE Study of the Neuro-Spinal Scaffold™

Published: August 17, 2016

Conversion Rate to Date is Four Times the Rate in Natural History Databases CAMBRIDGE, Mass. (Aug 17, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the ninth patient implanted with the Neuro-Spinal Scaffold™ in the INSPIRE study has improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury in the time between the two and three-month evaluations. This is the fifth out of the eight patients (62.5% conversion rate) in followup to have had an AIS grade improvement to date. Several large natural history databases indicate that fewer than 16% of patients with complete thoracic injuries […]

View Article
InVivo Therapeutics Appoints Pamela Stahl as Chief Commercial Officer

Published: August 11, 2016

CAMBRIDGE, Mass. (Aug 11, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Pamela Stahl to the newly-created position of Chief Commercial Officer (CCO), effective September 14, 2016. In this role, she will be responsible for building a comprehensive global commercial strategy that includes developing the company’s sales, reimbursement, and marketing strategies across key market segments to ensure a clear path for growth. Prior to joining InVivo, Ms. Stahl served for 10 years in various roles of increasing responsibility at UnitedHealthcare, most recently as Chief Executive Officer, Community Health Plan of Wisconsin. In that role, she was […]

View Article
InVivo Therapeutics Reports 2016 Second Quarter Financial Results and Business Update

Published: August 4, 2016

CAMBRIDGE, Mass. (August 4, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the quarter ended June 30, 2016. Mark Perrin, InVivo’s Chief Executive Officer and Chairman, said, “The second quarter was one marked by continued advancements and outreach. In the INSPIRE study, a fourth patient converted from a complete to an incomplete spinal cord injury, putting us one step closer to achieving the Objective Performance Criterion. The InVivo story was disseminated to life science professionals through our article in Life Science Leader; to researchers through our presentations at the 34th Annual Symposium of the National Neurotrauma […]

View Article
InVivo Therapeutics Announces Ben Taub Hospital/Baylor College of Medicine as New Site for INSPIRE Study

Published: July 18, 2016

CAMBRIDGE, Mass. (July 18, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Ben Taub Hospital in Houston, TX has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. The Ben Taub Hospital, located in the heart of the Texas Medical Center, is staffed by the Baylor College of Medicine and is the central clinical care facility for the Harris Health System. “I’m thrilled to bring the INSPIRE study to the Ben Taub Hospital,” […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.